[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@stocksdd Avatar @stocksdd Stocks DD

Stocks DD posts on X about $mreo, $rare, $azn, $nvs the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #


Social category influence finance XXXXX% cryptocurrencies XXX% stocks XXXX% currencies XXXX%

Social topic influence $mreo 10.34%, $rare 6.9%, $azn 3.45%, $nvs 3.45%, $nktr 3.45%, $abvx 3.45%, $pali 3.45%, $qure 3.45%, stocks 3.45%, dd XXXX%

Top accounts mentioned or mentioned by @javier944712106 @sharkbiotech @pharmdca @semodough @feldtinvesting @almightyzeeza @stephanklingel1 @wz2013 @wkissel @maximusholla @sanofi @revshark @ej23ny @mereobiopharma @tonythearena @avidresearch @darrenestes @seedy19tron @rxgongivit2ya @tcfftk

Top assets mentioned SuperRare (RARE) AstraZeneca PLC (AZN) Novartis AG (NVS) uniQure N.V. (QURE)

Top Social Posts #


Top posts by engagements in the last XX hours

"@FeldtInvesting @TCFFTK $MREO buyout rumor from X years ago. These companies are their business partners $AZN $NVS $RARE $nktr $abvx $pali $qure"
X Link @stocksdd 2025-10-13T14:08Z XXX followers, XXX engagements

"@medstudentinvst @DarrenEstes @Javier944712106 @AndrewS87261985 mgmt stated if X p3 trial hits stat sig & the other doesn't but end pt trends r good drug likely will get approved. Wth just X mth to go mgmt stated that in cosmic trial they're seeing much higher fracture rates in Bisphos group than in setrusumab. $MREO"
X Link @stocksdd 2025-10-06T17:42Z XXX followers, XXX engagements

"@medstudentinvst @DarrenEstes @Javier944712106 @AndrewS87261985 $Mreo is simple. mcap -cash= $260m. u get 1(or X if u incl Alvelostat) late stage assets & $245m mil paymt+2-digit US sales royalties to bottomline. They r lean. My guess is if a setrusu p3 trial fails they may try to salvage setrusu by designing a new trial w less variability"
X Link @stocksdd 2025-10-06T22:32Z XXX followers, XXX engagements